# US 10,370,725 B2 · FGR fusions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,370,725 B2
- Document ID: US10370725B2
- Status: Granted
- Kind: B2
- Application number: 15/326,368
- Filed: 2015-07-15
- Published: 2017-07-27
- Granted: 2019-08-06
- Earliest claimed: 2014-07-17
- Assignees: Blueprint Medicines Corporation
- Applicants: Blueprint Medicines Corporation
- Inventors: Nicolas Stransky; Ethan G. Cerami
- Web page: https://patentgrep.com/patent/US10370725B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12N 15/1138: {against receptors or cell surface proteins}
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

FGR (feline Gardner-Rasheed sarcoma viral oncogene homolog) fusions are described herein. Further provided are methods of diagnosing and treating diseases or disorders associated with FGR fusions, such as conditions mediated by FGR aberrant activity, or overexpression.

## Claims

### Claim 1

A method of detecting in a patient a WASF2:FGR gene fusion, said method comprising:
a) contacting a biological sample from the patient with an oligonucleotide that hybridizes to or amplifies the WASF2:FGR gene fusion of SEQ ID NO:1 or a portion thereof comprising a fusion junction; and
b) detecting binding between the WASF2:FGR gene fusion and the oligonucleotide or amplification of the WASF2:FGR gene fusion.

### Claim 2 (depends on 1)

The method of claim 1, wherein the oligonucleotide hybridizes under stringent conditions to (a) a fragment of SEQ ID NO:1 comprising nucleotides 178-187 of SEQ ID NO:1, or (b) a complementary oligonucleotide of (a).

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient is suffering from or susceptible to a cancer.

### Claim 4 (depends on 3)

The method of claim 3, wherein the cancer is lung squamous carcinoma, ovarian serous cystadenocarcinoma, cutaneous melanoma, uterine carcinosarcoma, or esophageal carcinoma.

### Claim 5 (depends on 4)

The method of claim 4, wherein the cancer is lung squamous carcinoma.

### Claim 6 (depends on 4)

The method of claim 4, wherein the cancer is ovarian serous cystadenocarcinoma.

### Claim 7 (depends on 4)

The method of claim 4, wherein the cancer is cutaneous melanoma.

### Claim 8 (depends on 4)

The method of claim 4, wherein the cancer is uterine carcinosarcoma.

### Claim 9 (depends on 4)

The method of claim 4, wherein the cancer is esophageal carcinoma.